Article Versions Notes

Nascimento da Cruz AC, Brondani DJ, I´talo de Santana T, Oliveira da Silva L, da Oliveira Borba EF, de Faria AR, Ferreira Cavalcanti de Albuquerque J, Piessard S, Matos Ximenes R, Baratte B, et al. Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents. Pharmaceuticals. 2019; 12(4):169. https://doi.org/10.3390/ph12040169

Nascimento da Cruz, Anne Cecília, Dalci José Brondani, Temístocles I´talo de Santana, Lucas Oliveira da Silva, Elizabeth Fernanda da Oliveira Borba, Antônio Rodolfo de Faria, Julianna Ferreira Cavalcanti de Albuquerque, Sylvie Piessard, Rafael Matos Ximenes, Blandine Baratte, and et al. 2019. "Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents" Pharmaceuticals 12, no. 4: 169. https://doi.org/10.3390/ph12040169

Nascimento da Cruz, A. C., Brondani, D. J., I´talo de Santana, T., Oliveira da Silva, L., da Oliveira Borba, E. F., de Faria, A. R., Ferreira Cavalcanti de Albuquerque, J., Piessard, S., Matos Ximenes, R., Baratte, B., Bach, S., Ruchaud, S., Bezerra Mendonça Junior, F. J., Bazin, M. -A., Montenegro Rabello, M., Hernandes, M. Z., Marchand, P., & Gonçalves da Silva, T. (2019). Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents. Pharmaceuticals, 12(4), 169. https://doi.org/10.3390/ph12040169